Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561690 · ClinicalTrials.gov registry record · Phase 2
A Study of ARRY-502 in Patients With Persistent Asthma
A Phase 2 study of Asthma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT01561690: Completed Phase 2 study of Asthma, sponsored by Pfizer.
NCT01561690 is a Phase 2 study of Asthma that has completed, run by Pfizer. The registered enrollment target is 184 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01561690, a Phase 2 study of Asthma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.
Conditions Studied
Interventions
- DRUG Placebo; oral
- DRUG ARRY-502, CRTh2 antagonist; oral
Study Locations (20)
California
- Allergy & Asthma Specialists Medical Group - Huntington Beach
- Allergy Medical Clinic - Research Division - Los Angeles
- California Allergy & Asthma Med. Group - Los Angeles
- Southern California Institute for Respiratory Diseases Inc - Los Angeles
- Southern California Research - Mission Viejo
- Peninsula Research Associates - Rolling Hills Estates
- Allergy Associates Medical Group - San Diego
Florida
- Clinical Neuroscience Solutions - Jacksonville
- Pulmonary Disease Specialists - Kissimmee
- South Florida Research Trials - Miami
- Allergy & Asthma Diagnostic Treatment Center - Tallahassee
- Florida Pulmonary Research Institute - Winter Park
Colorado
- Colorado Allergy and Asthma Center - Centennial
- IMMUNOe International Research Centers - Centennial
- Asthma & Allergy Associates PC - Colorado Springs
- Rocky Mountain Center for Clinical Research - Wheat Ridge
Idaho
- Idaho Research - Eagle
Illinois
- Sneeze, Wheeze & Itch - Normal
Maryland
- Chesapeake Clinical Research Inc - Baltimore
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2012-04-02 |
| Est. Completion | 2013-06-10 |
| Phase | Phase 2 |
What the finished NCT01561690 record still lists
NCT01561690 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo; oral is the first listed.
NCT01561690 names 20 study sites across 7 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01561690 about?
NCT01561690 is a clinical study titled "A Study of ARRY-502 in Patients With Persistent Asthma". This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this ...
What is the current status of trial NCT01561690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2012-04-02. Estimated completion is 2013-06-10.
What conditions does trial NCT01561690 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01561690?
The interventions under investigation include: Placebo; oral (DRUG), ARRY-502, CRTh2 antagonist; oral (DRUG).
Who is sponsoring clinical trial NCT01561690?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01561690 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01561690's enrollment target sits among peer trials
184 171st of 374 higher than 204 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI